1949. Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo 1960. A critical qppraisal of point of care coagulation testing in critically ill pati…
1365. Global public awarness of venous thromboembolism 1372. Venous thrombosis and cancer from mouse models to clinical trials 1383. Factor XI and contact activation as targets for anthitrombotic…
1175. Management of superficial vein thrombosis 1184. Hemophilia B molecular pathogenesis and mutation analysis 1196. Anticoagulation management during multivessel coronary artery bypass graftin…
893. Human platelet IgG Fc receptor FcyRIIA in immunity and thrombosis 909. Dysfibrinogemia from molecular anomalies to clinical manifestations and management 920. Does the response to aspirin a…
347. Active metabolite concentration of clopidogrel in patients taking different doses of aspirin results of the interaction trial 353. Real world variability in dabigatran levels in patients wit…
505. Recombinant soluble thrombomodulin in severe sepsis a systematic review and meta analysis 508. Recombinant human soluble thrombomodulin in severe sepsis a systematic review and meta analysis…
699. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation insights from the RE-LY trial 708. Risk of ischemic stroke associated with non…
597. Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis 608. Hematology journals do not sufficiently adhere to reporting guidelines: a systemati…
835. Ibrutinib-associated bleeding: pathogenesis, management adn risk reduction strategies 848. Long-term treatment of cancer-associated Thrombosis: the choice of the optimal anticoagulant 858. I…
1541. C-reative protein gene polymorphism preditct the risk of thromboboembolic stroke in patiens with atrial fibrillation a more than 10-year prospective follow-up study 1547. Assement of clinica…